TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07181499: A Study Evaluating the Efficacy and Safety of Pemetrexed Combined With Platinum-Based Chemotherapy Followed by Befotertinib in Patients With Non-Small Cell Lung Cancer After Third-Generation EGFR TKI Resistance

Sponsor: Betta Pharmaceuticals Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 28 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,913,600

Rescue Site Savings

+$3,880,800

Unlock Full NCT07181499 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07181499 Rescue Dossier →